<p>Vaxart Inc. has announced the publication of data from a double-blind, placebo-controlled Phase 1 clinical trial evaluating its single-dose, oral bivalent norovirus vaccine candidate in post-partum, breastfeeding women. The study, now published in npj Vaccines, demonstrated that the vaccine was safe, well-tolerated, and induced significant increases in norovirus-specific antibodies in both serum and breast milk. Additionally, norovirus-specific IgA was detected in the stool of breastfed infants, with a positive correlation observed between breast milk IgA and infant stool IgA levels, suggesting passive transfer of immunity. Topline safety and immunogenicity results were initially reported in April 2024. Vaxart plans to initiate the next clinical trial of its norovirus oral vaccine candidate in 2026, pending partnership or additional funding. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxart Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9626218) on January 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

Vaxart Reports Positive Phase 1 Results for Oral Norovirus Vaccine in Lactating Women